<?xml version='1.0' encoding='utf-8'?>
<document id="28038962"><sentence text="Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis."><entity charOffset="64-75" id="DDI-PubMed.28038962.s1.e0" text="bedaquiline" /><entity charOffset="80-89" id="DDI-PubMed.28038962.s1.e1" text="lopinavir" /><entity charOffset="90-99" id="DDI-PubMed.28038962.s1.e2" text="ritonavir" /><entity charOffset="103-113" id="DDI-PubMed.28038962.s1.e3" text="nevirapine" /><pair ddi="false" e1="DDI-PubMed.28038962.s1.e0" e2="DDI-PubMed.28038962.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28038962.s1.e0" e2="DDI-PubMed.28038962.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28038962.s1.e0" e2="DDI-PubMed.28038962.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s1.e0" e2="DDI-PubMed.28038962.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28038962.s1.e1" e2="DDI-PubMed.28038962.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28038962.s1.e1" e2="DDI-PubMed.28038962.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s1.e1" e2="DDI-PubMed.28038962.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28038962.s1.e2" e2="DDI-PubMed.28038962.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s1.e2" e2="DDI-PubMed.28038962.s1.e3" /></sentence><sentence text="Bedaquiline and its metabolite M2 are metabolised by CYP3A4"><entity charOffset="0-11" id="DDI-PubMed.28038962.s2.e0" text="Bedaquiline" /></sentence><sentence text=" The antiretrovirals ritonavir-boosted lopinavir (LPV/r) and nevirapine inhibit and induce CYP3A4, respectively"><entity charOffset="21-30" id="DDI-PubMed.28038962.s3.e0" text="ritonavir" /><entity charOffset="39-48" id="DDI-PubMed.28038962.s3.e1" text="lopinavir" /><entity charOffset="50-53" id="DDI-PubMed.28038962.s3.e2" text="LPV" /><entity charOffset="61-71" id="DDI-PubMed.28038962.s3.e3" text="nevirapine" /><pair ddi="false" e1="DDI-PubMed.28038962.s3.e0" e2="DDI-PubMed.28038962.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28038962.s3.e0" e2="DDI-PubMed.28038962.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28038962.s3.e0" e2="DDI-PubMed.28038962.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s3.e0" e2="DDI-PubMed.28038962.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28038962.s3.e1" e2="DDI-PubMed.28038962.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28038962.s3.e1" e2="DDI-PubMed.28038962.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s3.e1" e2="DDI-PubMed.28038962.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28038962.s3.e2" e2="DDI-PubMed.28038962.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s3.e2" e2="DDI-PubMed.28038962.s3.e3" /></sentence><sentence text=" Here we aimed to quantify nevirapine and LPV/r drug-drug interaction effects on bedaquiline and M2 in patients co-infected with HIV and multidrug-resistant tuberculosis (MDR-TB) using population pharmacokinetic (PK) analysis and compare these with model-based predictions from single-dose studies in subjects without TB"><entity charOffset="27-37" id="DDI-PubMed.28038962.s4.e0" text="nevirapine" /><entity charOffset="81-92" id="DDI-PubMed.28038962.s4.e1" text="bedaquiline" /><entity charOffset="42-52" id="DDI-PubMed.28038962.s4.e2" text="LPV" /><pair ddi="false" e1="DDI-PubMed.28038962.s4.e0" e2="DDI-PubMed.28038962.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28038962.s4.e0" e2="DDI-PubMed.28038962.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s4.e0" e2="DDI-PubMed.28038962.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28038962.s4.e2" e2="DDI-PubMed.28038962.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s4.e2" e2="DDI-PubMed.28038962.s4.e1" /></sentence><sentence text=" An observational PK study was performed in three groups of MDR-TB patients during bedaquiline maintenance dosing: HIV-seronegative patients (n = 17); and HIV-infected patients using antiretroviral therapy including nevirapine (n = 17) or LPV/r (n = 14)"><entity charOffset="83-94" id="DDI-PubMed.28038962.s5.e0" text="bedaquiline" /><entity charOffset="216-226" id="DDI-PubMed.28038962.s5.e1" text="nevirapine" /><entity charOffset="239-248" id="DDI-PubMed.28038962.s5.e2" text="LPV" /><pair ddi="false" e1="DDI-PubMed.28038962.s5.e0" e2="DDI-PubMed.28038962.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28038962.s5.e0" e2="DDI-PubMed.28038962.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28038962.s5.e0" e2="DDI-PubMed.28038962.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s5.e1" e2="DDI-PubMed.28038962.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28038962.s5.e1" e2="DDI-PubMed.28038962.s5.e2" /></sentence><sentence text=" Bedaquiline and M2 samples were collected over 48 h post-dose"><entity charOffset="1-12" id="DDI-PubMed.28038962.s6.e0" text="Bedaquiline" /></sentence><sentence text=" A previously developed PK model of MDR-TB patients was used as prior information to inform parameter estimation using NONMEM" /><sentence text=" The model was able to describe bedaquiline and M2 concentrations well, with estimates close to their priors and earlier model-based interaction effects from single-dose studies"><entity charOffset="32-43" id="DDI-PubMed.28038962.s8.e0" text="bedaquiline" /></sentence><sentence text=" Nevirapine changed bedaquiline clearance to 82% (95% CI 67-99%) and M2 clearance to 119% (92-156%) of their original values, indicating no clinically significant interaction"><entity charOffset="1-11" id="DDI-PubMed.28038962.s9.e0" text="Nevirapine" /><entity charOffset="20-31" id="DDI-PubMed.28038962.s9.e1" text="bedaquiline" /><pair ddi="false" e1="DDI-PubMed.28038962.s9.e0" e2="DDI-PubMed.28038962.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28038962.s9.e0" e2="DDI-PubMed.28038962.s9.e1" /></sentence><sentence text=" LPV/r substantially reduced bedaquiline clearance to 25% (17-35%) and M2 clearance to 59% (44-69%) of original values"><entity charOffset="29-40" id="DDI-PubMed.28038962.s10.e0" text="bedaquiline" /><entity charOffset="1-11" id="DDI-PubMed.28038962.s10.e1" text="LPV" /><pair ddi="false" e1="DDI-PubMed.28038962.s10.e1" e2="DDI-PubMed.28038962.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28038962.s10.e1" e2="DDI-PubMed.28038962.s10.e0" /></sentence><sentence text=" This work confirms earlier model-based predictions of nevirapine and LPV/r interaction effects on bedaquiline and M2 clearance from subjects without TB in single-dose studies, in MDR-TB/HIV co-infected patients studied here"><entity charOffset="55-65" id="DDI-PubMed.28038962.s11.e0" text="nevirapine" /><entity charOffset="99-110" id="DDI-PubMed.28038962.s11.e1" text="bedaquiline" /><entity charOffset="70-80" id="DDI-PubMed.28038962.s11.e2" text="LPV" /><pair ddi="false" e1="DDI-PubMed.28038962.s11.e0" e2="DDI-PubMed.28038962.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28038962.s11.e0" e2="DDI-PubMed.28038962.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s11.e0" e2="DDI-PubMed.28038962.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28038962.s11.e2" e2="DDI-PubMed.28038962.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s11.e2" e2="DDI-PubMed.28038962.s11.e1" /></sentence><sentence text=" To normalise bedaquiline exposure in patients with concomitant LPV/r therapy, an adjusted bedaquiline dosing regimen is proposed for further study"><entity charOffset="14-25" id="DDI-PubMed.28038962.s12.e0" text="bedaquiline" /><entity charOffset="91-102" id="DDI-PubMed.28038962.s12.e1" text="bedaquiline" /><entity charOffset="64-74" id="DDI-PubMed.28038962.s12.e2" text="LPV" /><pair ddi="false" e1="DDI-PubMed.28038962.s12.e0" e2="DDI-PubMed.28038962.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28038962.s12.e0" e2="DDI-PubMed.28038962.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s12.e0" e2="DDI-PubMed.28038962.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28038962.s12.e2" e2="DDI-PubMed.28038962.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28038962.s12.e2" e2="DDI-PubMed.28038962.s12.e1" /></sentence><sentence text="" /></document>